Literature DB >> 21709094

In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions.

Will Stubbings1, Pamela Leow, Goh Chee Yong, Falicia Goh, Barbara Körber-Irrgang, Michael Kresken, Rainer Endermann, Harald Labischinski.   

Abstract

Finafloxacin is a novel fluoroquinolone that exhibits enhanced antibacterial activity under acidic conditions. The aim of this study was to define the in vitro pH-activity relationship. Finafloxacin exhibited optimal antibacterial activity between pH 5.0 and 6.0 at which MICs were 4- to 8-fold lower than those determined at neutral pH. These observations were then confirmed against a larger collection of bacteria. These data suggest that finafloxacin could potentially offer a therapeutic advantage within acidic foci of infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21709094      PMCID: PMC3165343          DOI: 10.1128/AAC.00833-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.

Authors:  Paul G Higgins; Will Stubbings; Hilmar Wisplinghoff; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2010-01-25       Impact factor: 5.191

Review 2.  Hyperinflammation in airways of cystic fibrosis patients: what's new?

Authors:  Jacky Jacquot; Olivier Tabary; Annick Clement
Journal:  Expert Rev Mol Diagn       Date:  2008-07       Impact factor: 5.225

3.  Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions.

Authors:  Sang Sun Yoon; Ray Coakley; Gee W Lau; Sergei V Lymar; Benjamin Gaston; Ahmet C Karabulut; Robert F Hennigan; Sung-Hei Hwang; Garry Buettner; Michael J Schurr; Joel E Mortensen; Jane L Burns; David Speert; Richard C Boucher; Daniel J Hassett
Journal:  J Clin Invest       Date:  2006-01-26       Impact factor: 14.808

Review 4.  Antimicrobial safety: focus on fluoroquinolones.

Authors:  Robert C Owens; Paul G Ambrose
Journal:  Clin Infect Dis       Date:  2005-07-15       Impact factor: 9.079

5.  Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine.

Authors:  Axel Dalhoff; Will Stubbings; Sabine Schubert
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

6.  Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance.

Authors:  Nadine-C Emrich; Anke Heisig; Will Stubbings; Harald Labischinski; Peter Heisig
Journal:  J Antimicrob Chemother       Date:  2010-10-12       Impact factor: 5.790

7.  Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide.

Authors:  A Dalhoff; S Schubert; U Ullmann
Journal:  Infection       Date:  2005-12       Impact factor: 3.553

8.  Conditions affecting the results of susceptibility testing for the quinolone compounds.

Authors:  S M Smith; R H Eng; C E Cherubin
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

  8 in total
  24 in total

Review 1.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

Review 2.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 3.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

Review 4.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

5.  Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.

Authors:  Max Taubert; Joseph Chiesa; Mark Lückermann; Carsten Fischer; Axel Dalhoff; Uwe Fuhr
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

6.  Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic Enterobacteriaceae.

Authors:  Maria Loose; Isabell Link; Kurt G Naber; Florian M E Wagenlehner
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

Review 7.  Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria.

Authors:  Neelam Taneja; Harsimran Kaur
Journal:  Microbiol Insights       Date:  2016-03-20

8.  High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones.

Authors:  Jung Won Lee; Nayoung Kim; Ryoung Hee Nam; Jung Mogg Kim; Jong Youn Park; Sun Min Lee; Joo Sung Kim; Dong Ho Lee; Hyun Chae Jung
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

9.  Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates.

Authors:  Andreas Vente; Christine Bentley; Mark Lückermann; Paul Tambyah; Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

10.  Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.

Authors:  F Wagenlehner; M Nowicki; C Bentley; M Lückermann; S Wohlert; C Fischer; A Vente; K Naber; A Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.